EP Patent

EP2217235A4 — PROTEIN INHIBITORS PIM KINASES, COMPOSITIONS AND METHODS FOR TREATING CANCER

Assigned to MUSC Foundation for Research and Development · Expires 2011-01-12 · 15y expired

What this patent protects

Patent listed against ruxolitinib-phosphate.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: EP2217235A4
Jurisdiction: EP
Classification: —
Expires: 2011-01-12
Drug substance claim: No
Drug product claim: No
Assignee: MUSC Foundation for Research and Development
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.